We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $58.06, marking a -0.77% move from the previous day. This change lagged the S&P 500's daily gain of 2.6%. At the same time, the Dow added 2.83%, and the tech-heavy Nasdaq lost 0.05%.
Prior to today's trading, shares of the company had lost 18.95% over the past month. This has lagged the Medical sector's loss of 8.72% and the S&P 500's loss of 12.9% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$2.30 per share. This would mark a year-over-year decline of 37.72%. Our most recent consensus estimate is calling for quarterly revenue of $4.08 million, up 397.56% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$9.17 per share and revenue of $14.21 million. These results would represent year-over-year changes of -295.11% and -98.45%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.72% higher within the past month. CRISPR Therapeutics AG is currently a Zacks Rank #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $58.06, marking a -0.77% move from the previous day. This change lagged the S&P 500's daily gain of 2.6%. At the same time, the Dow added 2.83%, and the tech-heavy Nasdaq lost 0.05%.
Prior to today's trading, shares of the company had lost 18.95% over the past month. This has lagged the Medical sector's loss of 8.72% and the S&P 500's loss of 12.9% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$2.30 per share. This would mark a year-over-year decline of 37.72%. Our most recent consensus estimate is calling for quarterly revenue of $4.08 million, up 397.56% from the year-ago period.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$9.17 per share and revenue of $14.21 million. These results would represent year-over-year changes of -295.11% and -98.45%, respectively.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.72% higher within the past month. CRISPR Therapeutics AG is currently a Zacks Rank #4 (Sell).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 59, which puts it in the top 24% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.